10x Genomics Past Earnings Performance
Past criteria checks 0/6
10x Genomics's earnings have been declining at an average annual rate of -3.4%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 20.3% per year.
Key information
-3.4%
Earnings growth rate
12.2%
EPS growth rate
| Life Sciences Industry Growth | 36.9% |
| Revenue growth rate | 20.3% |
| Return on equity | -25.3% |
| Net Margin | -29.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How 10x Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 630 | -183 | 331 | 260 |
| 30 Jun 24 | 632 | -240 | 332 | 261 |
| 31 Mar 24 | 625 | -264 | 337 | 269 |
| 31 Dec 23 | 619 | -255 | 336 | 268 |
| 30 Sep 23 | 591 | -223 | 331 | 267 |
| 30 Jun 23 | 568 | -172 | 322 | 268 |
| 31 Mar 23 | 536 | -174 | 312 | 267 |
| 31 Dec 22 | 516 | -166 | 296 | 264 |
| 30 Sep 22 | 504 | -167 | 289 | 264 |
| 30 Jun 22 | 498 | -142 | 278 | 251 |
| 31 Mar 22 | 499 | -89 | 267 | 234 |
| 31 Dec 21 | 490 | -58 | 258 | 212 |
| 30 Sep 21 | 459 | -455 | 244 | 190 |
| 30 Jun 21 | 406 | -504 | 233 | 165 |
| 31 Mar 21 | 333 | -533 | 209 | 139 |
| 31 Dec 20 | 299 | -543 | 202 | 123 |
| 30 Sep 20 | 262 | -134 | 185 | 112 |
| 30 Jun 20 | 251 | -78 | 166 | 104 |
| 31 Mar 20 | 264 | -49 | 154 | 94 |
| 31 Dec 19 | 246 | -31 | 131 | 83 |
| 30 Sep 19 | 221 | -100 | 119 | 68 |
| 30 Jun 19 | 197 | -105 | 105 | 57 |
| 31 Mar 19 | 170 | -105 | 94 | 51 |
| 31 Dec 18 | 146 | -112 | 88 | 48 |
| 31 Dec 17 | 71 | -19 | 47 | 32 |
Quality Earnings: 0A88 is currently unprofitable.
Growing Profit Margin: 0A88 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0A88 is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare 0A88's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A88 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 0A88 has a negative Return on Equity (-25.26%), as it is currently unprofitable.